Aclaris is a biopharmaceutical company that strives to translate scientific discoveries into everyday victories in dermatology, and beyond. Learn about our pipeline.
Location: United States, Pennsylvania, Wayne
Employees: 51-200
Total raised: $62M
Founded date: 2012
Investors 9
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.05.2016 | - | $20M | - |
| 02.10.2014 | Series B | $21M | - |
| 24.10.2012 | Series A | $21M | - |
Mentions in press and media 15
| Date | Title | Description |
| 18.11.2024 | Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets | Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales mi... |
| 07.12.2021 | Aclaris Therapeutics : Virtual R&D Day Presentation | EMPOWERING PATIENTS THROUGH KINOME INNOVATION Aclaris Therapeutics Virtual R&D Day The Productivity of the Platform December 7, 2021 © Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0677 12/21) Cautionary Note Reg... |
| 18.11.2021 | Aclaris Therapeutics : Overview - November 2021 | EMPOWERING PATIENTS THROUGH KINOME INNOVATION Company Overview November 2021 © Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0673 11/21) Cautionary Note Regarding Forward-Looking Statements Any statements contained i... |
| 27.05.2016 | Aclaris Therapeutics Announces $20.0 Million Private Placement | MALVERN, Pa., May 27, 2016 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, announced today that it has entered into a stock purchase agreement with a group of institutional acc... |
| 18.08.2015 | Malvern biotech company files for $86M IPO | Aclaris Therapeutics, a Malvern biotech company that’s developing topical drugs for skin lesions, filed for an $86 million IPO, according to an SEC filing. The company plans to start the third phase of clinical trials, where it will test th... |
| 02.10.2014 | Aclaris Therapeutics Closes $21M Series B | MALVERN, PA, Privately-held specialty pharmaceutical company, announced today that it has closed on a $21 million Series B financing. >> Click here for more funding data on Aclaris Therapeutics >> To export Aclaris Therapeut... |
| 02.10.2014 | Aclaris Therapeutics Closes $21M Series B Financing | Aclaris Therapeutics, Inc., a Malvern, Pennsylvania-based specialty pharmaceutical company, closed on a $21m Series B financing. Backers included existing investors Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Founded in Augu... |
| 02.01.2014 | Biopharma company raises $21.5M to treat inflammatory skin disorders | LXR agonists have generated interest as a source of life science innovation with the potential to treat conditions such as atherosclerosis and Alzheimer’s disease. Dr. Neal Walker is a dermatologist and serial entrepreneur who will serve as... |
| 04.10.2013 | From gamification to personalized medicine, here’s a list of companies pitching at IMPACT | CardioReady (@CardioReady) is all about automated external defibrillators and helps customers evaluate, buy, install, track, and maintain them. Healthper (@HealthPer) works with employer wellness plans using a mix of gamification and incent... |
| 24.10.2012 | Aclaris Therapeutics Secures $21M in Series A Financing | Aclaris Therapeutics, Inc., a Malvern, PA-based specialty pharmaceutical company dedicated to developing dermatological therapeutics, has secured $21m in Series A financing. The round was led by Vivo Ventures and Fidelity Biosciences with p... |
Show more